Covid 19 Research using Clinical Trials (Home Page)
Report for D058070: Asymptomatic Diseases NIH
(Synonyms: Asymptomatic Diseases)
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (8)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug564 | COVID-19 patients Wiki | 0.82 |
| drug1204 | Guduchi Ghan Vati Wiki | 0.58 |
| drug2926 | To assess for development of IgG antibodies against SARS-CoV2 Wiki | 0.58 |
| drug559 | COVID-19 e-package: Psychological wellbeing for healthcare workers Wiki | 0.58 |
| drug1312 | Hydroxychloroquine Sulfate Regular dose Wiki | 0.41 |
| drug1311 | Hydroxychloroquine Sulfate Loading Dose Wiki | 0.41 |
| drug654 | Chloroquine Wiki | 0.20 |
| drug2122 | Placebo Wiki | 0.03 |
Correlated MeSH Terms (7)
| Name (Synonyms) | Correlation | |
|---|---|---|
| D003333 | Coronaviridae Infections NIH | 0.26 |
| D012327 | RNA Virus Infections NIH | 0.26 |
| D014777 | Virus Diseases NIH | 0.07 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.06 |
| D003141 | Communicable Diseases NIH | 0.05 |
| D018352 | Coronavirus Infections NIH | 0.05 |
| D007239 | Infection NIH | 0.03 |
Correlated HPO Terms (0)
| Name (Synonyms) | Correlation |
|---|
There are 3 clinical trials
Clinical Trials
1 Use and Dosage of Hydroxychloroquine and Chloroquine to Convert Real Time Polymerase Chain Reaction (RT-PCR) Positive Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Coronavirus Infectious Disease 2019 (COVID-19) Patients to RT- PCR-Negative as a Means to Reduce Hospitalization Rate
To create a protocol for treatment of Pakistani patients with SARS-CoV-2 infection with an intent to reduce burden on institutional healthcare services by determining efficacy of different quinone drug dosing regimens in controlling SARS-CoV-2 infection for asymptomatic patients.
NCT04346667 SARS-CoV-2 Coronavirus Infection Asymptomatic Condition COVID-19 Drug: Hydroxychloroquine Sulfate Regular dose Drug: Hydroxychloroquine Sulfate Loading Dose Drug: Chloroquine Drug: Placebo MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome Asymptomatic Diseases
Primary Outcomes
Description: Percentage of patients who become RT-PCR negative with two RT-PCR tests performed at day 6 and day 7
Measure: RT-PCR negative status Time: 6-7 daysSecondary Outcomes
Description: Time to progression to next stage of SARS-CoV-2 disease severity index
Measure: Progression of symptoms Time: 7 daysDescription: Time to onset of fever (temperature greater than 100 degree F), cough, or shortness of breath (respiratory rate >22 per minute).
Measure: Development of Symptoms Time: 7 daysDescription: Drug related adverse events as determined by data safety and monitoring board (DSMB)
Measure: Adverse events Time: 7 days2 ScreenNC: A Study to Determine the Number of Asymptomatic Individuals Who Have Antibodies to the SARS-CoV-2 Infection
Purpose: To determine the number of asymptomatic individuals who have antibodies to SARS-CoV-2, the virus which causes COVID-19
NCT04367740 Asymptomatic Condition Infection Viral Coronavirus Infections Severe Acute Respiratory Syndrome Coronavirus 2 Coronaviridae Infections RNA Virus Infections Virus Diseases Communicable Disease Diagnostic Test: To assess for development of IgG antibodies against SARS-CoV2 MeSH:Infection Communicable Diseases Coronavirus Infections Severe Acute Respiratory Syndrome RNA Virus Infections Coronaviridae Infections Asymptomatic Diseases Virus Diseases
Primary Outcomes
Description: Presence or absence of IgG antibodies to SARS-CoV2
Measure: Percentage of Asymptomatic patients with an IgG response from SARS-CoV-2 infection. Time: at enrollmentSecondary Outcomes
Description: swab for presence of SARS-CoV-2 virus
Measure: Percentage of Asymptomatic patients with viral presence of SARS-CoV-2 infection. Time: at enrollment3 A Retrospective Study on Efficacy and Safety of Guduchi Ghan Vati for Covid-19 Asymptomatic Patients
Coronavirus disease 2019 (Covid-19) has been declared global emergency with immediate safety, preventative and curative measures to control the spread of virus. Confirmed cases are treated with clinical management as they are diagnosed but so far, there is no effective treatment or vaccine yet for Covid-19. With recommended guidelines of AYUSH Ministry, India, the use of Ayurveda for Covid-19 has increased; however, its efficacy and safety in Covid-19 confirmed patients remain unclear. Present study examined the efficacy and safety of one of the recommended Ayurveda drug (Guduchi Ghan Vati) compared with standard care for patients with asymptomatic Covid-19 patients.
NCT04480398 Covid19 Asymptomatic Condition Drug: Guduchi Ghan Vati MeSH:Asymptomatic Diseases
Primary Outcomes
Description: Virologic clearance indicates the duration from the first Covid‐19 positive result to the first Covid-19 negative result
Measure: Virologic clearance Time: 21 daysSecondary Outcomes
Description: change in the number of patients going from asymptomatic to moderately disease
Measure: Change in the number of patients going from asymptomatic to moderately disease Time: 10-days of hospital admissionDescription: Total duration of stay in hospital for complete recovery
Measure: Hospital Stay Time: 21 daysDescription: Clinically relevant adverse effects of Guduchi Ghan Vati (Disability, Discomfort reported)
Measure: Clinically relevant adverse effects Time: 21-days